An Antigenically Diverse, Representative Panel of Envelope Glycoproteins for Hepatitis C Virus Vaccine Development
TLDR
In this paper , the authors describe the selection and validation of a genetically and antigenically diverse reference panel of 15 HCV pseudoparticles (HCVpps) for neutralization assays, and propose that this multitier reference panel could be adopted as a standard for the measurement of neutralizing antibody potency and breadth, facilitating meaningful comparisons of neutralization results from vaccine studies in different laboratories.About:
This article is published in Gastroenterology.The article was published on 2022-02-01 and is currently open access. It has received 15 citations till now. The article focuses on the topics: Neutralization & Neutralizing antibody.read more
Citations
More filters
Journal ArticleDOI
Serum neutralization activity declines but memory B cells persist after cure of chronic hepatitis C
Akira Nishio,Sharika Hasan,Heiyoung Park,Nana Park,Jordan Salas,Eduardo Salinas,Lela Kardava,Paul Juneau,Nicole Frumento,Guido Massaccesi,Susan Moir,Justin R. Bailey,Arash Grakoui,Marc G. Ghany,Barbara Rehermann +14 more
TL;DR: In this article , archived sera and mononuclear cells were prospectively collected up to 18 years after cure of chronic hepatitis C virus infection to determine the role of HCV antigen in maintaining neutralizing antibody and B cell responses.
Journal ArticleDOI
Inactivated genotype 1a, 2a and 3a HCV vaccine candidates induced broadly neutralising antibodies in mice
Garazi Peña Alzua,Anne Finne Pihl,Anna Offersgaard,C. R. Duarte Hernandez,Zhenzhen Duan,Shan Feng,Ulrik Fahnøe,Christina Sølund,Nina Weis,Mansun Law,Jannick Prentoe,Jan Pravsgaard Christensen,Jens Bukh,Judith M. Gottwein +13 more
TL;DR: High-yield genotype 1–3 HCV could be developed as basis for inactivated vaccine candidates inducing broadly neutralising antibodies in mice supporting further preclinical development.
Journal ArticleDOI
Repeated exposure to heterologous hepatitis C viruses associates with enhanced neutralizing antibody breadth and potency
TL;DR: In this paper , the development of bNAbs in longitudinal plasma of HCV-infected persons with persistent infection or spontaneous clearance of multiple reinfections was investigated, and the breadth and potency of the antibody response increased upon exposure to multiple genetically distinct infections and with longer duration of viremia.
Journal ArticleDOI
Two-component vaccine consisting of virus-like particles displaying hepatitis C virus envelope protein 2 oligomers
Jannick Prentoe,Christoph M. Janitzek,Rodrigo Velázquez-Moctezuma,Andreas Soerensen,Thomas J. D. Jørgensen,Stine N. Clemmensen,Vladislav Soroka,Susan Thrane,Thor G. Theander,Morten Nielsen,Ali Salanti,Jens Bukh,Adam F. Sander +12 more
TL;DR: In this article , self-assembling virus-like particles (cVLPs) were used to display monomeric or oligomeric forms of hepatitis C virus sE2 (sE2mono or sE 2oligo).
Journal ArticleDOI
Optimization of the pseudoparticle system for standardized assessments of neutralizing antibodies against hepatitis C virus.
Ana Chumbe,Richard A. Urbanowicz,Kwinten Sliepen,Sylvie M. Koekkoek,Richard Molenkamp,Alexander W. Tarr,Jonathan K. Ball,Janke Schinkel,Marit J. van Gils +8 more
TL;DR: In this paper , a simplified and reproducible HCVpp neutralization protocol for studying a wide range of HCV variants was proposed, which can contribute to a better understanding of the antibody response during natural infection and help evaluate experimental HCV vaccines.
References
More filters
Journal ArticleDOI
MAFFT Multiple Sequence Alignment Software Version 7: Improvements in Performance and Usability
Kazutaka Katoh,Daron M. Standley +1 more
TL;DR: This version of MAFFT has several new features, including options for adding unaligned sequences into an existing alignment, adjustment of direction in nucleotide alignment, constrained alignment and parallel processing, which were implemented after the previous major update.
Journal ArticleDOI
Global Distribution and Prevalence of Hepatitis C Virus Genotypes
Jane P. Messina,Isla Humphreys,Abraham D. Flaxman,Anthony Brown,Graham S Cooke,Oliver G. Pybus,Eleanor Barnes +6 more
TL;DR: It is calculated that HCV genotype 1 is the most prevalent worldwide, comprising 83.4 million cases (46.2% of all HCV cases), approximately one‐third of which are in East Asia.
Journal ArticleDOI
Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: Updated criteria and genotype assignment web resource
D B Smith,Jens Bukh,Carla Kuiken,A. Scott Muerhoff,Charles M. Rice,Jack T. Stapleton,Peter Simmonds +6 more
TL;DR: This study represents a major update to the previous consensus HCV classification, incorporating additional sequence information derived from over 1,300 (near‐)complete genome sequences of HCV available on public databases in May 2013.
Journal ArticleDOI
Infectious Hepatitis C Virus Pseudo-particles Containing Functional E1–E2 Envelope Protein Complexes
TL;DR: Infectious pseudo-particles generated by displaying unmodified and functional HCV glycoproteins onto retroviral and lentiviral core particles may mimic the early infection steps of parental HCV and will be suitable for the development of much needed new antiviral therapies.
Journal ArticleDOI
Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents
Fasiha Kanwal,Fasiha Kanwal,Jennifer R. Kramer,Jennifer R. Kramer,Steven M. Asch,Steven M. Asch,Maneerat Chayanupatkul,Yumei Cao,Hashem B. El-Serag,Hashem B. El-Serag +9 more
TL;DR: In patients with SVR, the absolute risk of HCC remained high in patients with established cirrhosis, but among patients treated with DAA, SVR was associated with a considerable reduction in the risk ofHCC.